Viridian Therapeutics, Inc.
VRDN
$23.02
-$0.15-0.65%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 101.42% | 6.82% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 101.42% | 6.82% | |||
| Cost of Revenue | -7.80% | -16.26% | |||
| Gross Profit | 8.00% | 16.30% | |||
| SG&A Expenses | 42.13% | 14.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.81% | -7.97% | |||
| Operating Income | -8.69% | 7.98% | |||
| Income Before Tax | -21.18% | 12.84% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -21.18% | 12.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.18% | 12.84% | |||
| EBIT | -8.69% | 7.98% | |||
| EBITDA | -8.71% | 7.99% | |||
| EPS Basic | -16.15% | 15.92% | |||
| Normalized Basic EPS | -14.81% | 21.80% | |||
| EPS Diluted | -16.15% | 15.92% | |||
| Normalized Diluted EPS | -14.81% | 21.80% | |||
| Average Basic Shares Outstanding | 5.55% | 8.30% | |||
| Average Diluted Shares Outstanding | 5.55% | 8.30% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||